Abstract This retrospective study aimed to compare the accuracy of two nodal evaluation criteria using computed tomography after intra-arterial chemoradiation in nodepositive head and neck squamous cell carcinomas. Computed tomography was used to evaluate radiographic nodal response 4-8 weeks after intra-arterial chemoradiation. We compared the accuracy of two different criteria: criterion 1 (radiographic complete response was recorded in the absence of focal abnormalities and if the maximum diameter of the metastatic node was less than 15 mm), and criterion 2 (radiographic complete response was recorded in the absence of focal abnormalities and if the minimum diameter of metastatic nodes was less than 7 mm in level II and if the minimum diameter of metastatic nodes in the rest of the neck was less than 6 mm). Positive predictive values were criterion 1: 69.2%, criterion 2: 47.8%; negative predictive values were criterion 1: 88.5%, criterion 2: 90.5%. Positive likelihood ratios were criterion 1: 7.50, criterion 2: 3.06. The difference between each criteria was statistically significant using McNemar's test (p = 0.0016). Computed tomography evaluation accuracy of nodal response after intra-arterial chemoradiation was comparable to recent reports, and it was feasible to perform salvage neck dissection by computed tomography evaluation for nodal response. We recommend using criterion 1 because of its simplicity and reliability.
Introduction
Concurrent chemoradiation (CCRT) is the current standard treatment for both advanced unresectable head and neck squamous cell carcinomas (HNSCC) and resectable HNSCC for the purpose of preserving organ functions [1] [2] [3] . CCRT has also been shown to be effective for the treatment of nodal metastasis, therefore planned neck dissection (ND) for all node positive (N?) HNSCC patients who undergo CCRT is not considered feasible [4] .
It is shown that superselective intra-arterial infusion of cisplatin and concomitant radiotherapy (RADPLAT) has proved a promising treatment. RADPLAT efficacy of primary sites is high, and RADPLAT followed by planned ND is highly effective for controlling regional disease [5, 6] .
The traditional approach of planned ND for all N? HNSCC patients is becoming obsolete. However, it is very difficult to evaluate the presence or absence of nodal disease after therapy. Some patients show late failure of disease even if they are regarded as clinical complete response (CR). Therefore, an accurate evaluation of the treatment response after therapy is required, although few studies of nodal evaluation and criteria after CCRT have been reported. The current study therefore aimed to evaluate the accuracy and criteria of nodal response post-RADPLAT, and to determine whether a ''wait and see'' policy for N? HNSCC patients undergoing RADPLAT is acceptable.
Patients and methods

Patients
We retrospectively analyzed 65 patients (59 men and 6 women) with N? HNSCC who underwent RADPLAT in Hokkaido University Hospital, Japan, between October 1999 and April 2010. Median age was 59 years (range 41-74 years; mean, 58.3 years). The follow-up length of surviving patients ranged from 6 to 127.2 months (median 31.2 months, mean 39.6 months). The primary sites were 12 paranasal sinuses (10 maxillary sinuses, 2 ethmoid sinuses), 18 oropharynx, 27 hypopharynx, 5 larynx, 2 oral cavities, and 1 parotid gland (Table 1) .
T and N classification according to the American Joint Committee on Cancer (AJCC) staging system seventh edition 2010 is shown in Table 2 . Fifteen patients were diagnosed with N1, 35 with N2b, 13 with N2c, and 2 with N3.
Radiotherapy
The irradiation plan of 2006-2010 was 40 Gy in 20 fractions of 2 Gy over 4 weeks for the primary site and all nodal areas, immediately followed by a boost of 30 Gy in 15 fractions to the primary cancer and metastatic nodal area over additional 3 weeks (total dose, 70 Gy). Between 1999 and 2005, all nodal areas and the primary site were Fig. 1 Patient with Oropharyngeal cancer (T4aN2b) undergoing RADPLAT. a Pretreatment CT showed metastatic node (30 9 22 mm) in level II. b Post-treatment (60 days after RADPLAT) CT showed size decreasing node (7 9 6 mm) without focal abnormality. According to both criteria 1 and 2, this node was defined as rCR. This patient had no nodal recurrence and survived without disease 14 months after treatment 
Chemotherapy
Chemotherapy comprised 100-120 mg/m 2 superselective intra-arterial cisplatin administered a median of four times weekly (range 2-5 times, mean 3.7 times). Simultaneously, sodium thiosulfate was administered intravenously (24 g/ body) to provide effective cisplatin neutralization. In cases with large node metastasis, about 10 or 15% of the total cisplatin dose was selectively administered to the metastatic node. ''rN? or -'' was radiographic node positive or negative ''pN? or -'' was pathological node positive or negative after neck dissection ''Criterion 1'' defined less than 15 mm maximum diameter and no focal abnormality as radiographic node negative ''Criterion 2'' defined less than 7 mm minimum diameter in level II and less than 6 mm minimum diameter in rest of neck,and no focal abnormality as radiographic node negative Eur Arch Otorhinolaryngol (2012) 269:1671-1676 1673
Evaluation of nodal metastasis Pre-treatment nodal metastasis was evaluated by computed tomography (CT) and/or magnetic resonance imaging (MRI). Nodal response was assessed by CT scan 4-8 weeks after completion of initial therapy. A radiographic complete response (rCR) was recorded in the absence of focal abnormalities and if the maximum diameter of the metastatic node was less than 15 mm. In this criterion, focal abnormality included lucency, enhancement, and calcification. We defined this as ''criterion 1'' [7] . If residual node metastasis was clear, we performed early salvage ND. For patients assessed as rCR, we practiced a ''wait and see'' policy. We analyzed sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV), positive likelihood ratio, and negative likelihood ratio of CT evaluation, to determine the efficiency of this criterion.
Retrospectively, we applied another criterion using a different nodal size for different levels of the neck. In this criterion, rCR was recorded in the absence of focal abnormalities and if the minimum diameter of metastatic nodes was less than 7 mm in level II and if the minimum diameter of metastatic nodes in the rest of the neck was less than 6 mm. We defined this as ''criterion 2'' [8] . In addition, we also analyzed the sensitivity, specificity, NPV, PPV, positive likelihood ratio, and negative likelihood ratio of this criterion.
Patients were usually monitored monthly for recurrence in the first year, every couple of months in the second year, every 6 or 12 months thereafter. CT scans were routinely performed once every 3 months in the first year, every 6 or 12 months thereafter. If lymph node metastases enlarged, patients with resectable neck diseases were referred for dissection.
When there were no tumor cells found in a surgical specimen from ND, a pathological complete response (pCR) was recorded and nodal metastases of these cases were defined as be controlled by RADPLAT alone.
Statistics
The Kaplan-Meier method was applied for nodal control rate using JMP 5.0.1 J statistical software (SAS Institute, Cary, NC, USA). Time of interest was duration from the start of treatment to that of regional failure. The log-rank test was used to compare two group control rates, and McNemar's test was used to compare two different criteria.
Results
Forty-four patients (67.7%) did not show nodal recurrence. Two patients (3.1%) died of HNSCC without having undergone ND. Nineteen patients (29.2%) underwent ND at a median of 15.4 weeks (range 6.9-60.4 weeks, mean 18.8 weeks) after the completion of RADPLAT.
The 5-year nodal control rate of overall treatment (including salvage by ND) was 87.1%. The 5-year nodal control rate of RADPLAT alone (not including salvage by ND) was 75.3%. According to N-classification, 5-year nodal control rates of RADPLAT alone were 80% for N1 (n = 15), 75.1% for N2b-c (n = 48), and 50% for N3 (n = 2).
In the 32 patients who received cisplatin administration only to the primary site, the 5-year nodal control rate of RADPLAT alone was 78.1%; this rate was 72.3% in the 23 patients who received cisplatin administration to both primary and regional sites. There was no significant difference between these two groups (p = 0.74, log-rank test).
Analysis using criterion 1
According to criterion 1, 52 patients were considered to be rCR. Of these 52 patients, 10 underwent ND. Of these, seven patients underwent planned ND, and three patients underwent late salvage ND because of nodal re-enlargement. In two of seven patients undergoing planned ND, surgical specimens revealed residual pathological nodal metastases. In surgical specimens of all three patients undergoing late salvage ND, viable tumor cells were observed. Another patient suffered a re-enlarged metastatic node 28 weeks after initial treatment, but ND was not performed because of inoperable primary site recurrence. These six patients were false negative cases.
Thirteen patients were not considered to be rCR. Of these, four did not undergo ND because one patient refused surgery, and three patients were not indicated for ND due to simultaneous unresectable primary disease (one patient) and lung metastases (two patients). However, metastatic node of a patient who refused ND disappeared thereafter. In the remaining three patients, nodes did not re-enlarge until they died (median 19 months, range 18-22 months, ''Criterion 1'' defined less than 15 mm maximum diameter and no focal abnormality as radiographic node negative ''Criterion 2'' defined less than 7 mm minimum diameter in level II and less than 6 mm minimum diameter in rest of neck,and no focal abnormality as radiographic node negative after completion of RADPLAT). These four patients were considered false positive cases. Sensitivity of this criterion was 60%, specificity was 92%, NPV was 88.5%, PPV was 69.2%, positive likelihood ratio was 7.50, and negative likelihood ratio was 0.44 (Figs. 1, 2, 3 ).
Analysis using criterion 2
According to criterion 2, 42 patients were considered to be rCR; 7 of these 42 patients underwent ND (five planned ND, and two late salvage ND). In three of these seven patients undergoing ND, surgical specimens revealed pathological nodal metastases. Another patient suffered a re-enlarged metastatic node, but ND was not performed because of primary site recurrence. These four patients were false negative cases. Twenty-three patients were not considered to be rCR. Of these, 11 did not undergo ND. However, nodal re-enlargement was not recognized in all 11 patients. Another patient underwent ND, and pathological findings revealed no viable metastatic cells. These 12 patients were false positive cases. Sensitivity of this criterion was 73.3%, specificity was 76%, NPV was 90.5%, PPV was 47.8%, positive likelihood ratio was 3.06, and negative likelihood ratio was 0.35 (Tables 3, 4) . Table 5 shows the difference between criteria 1 and 2, which was statistically significant by McNemar's test (p = 0.0016). Ten patients evaluated as rCR by criterion 1 were not using criterion 2 (Table 6 ).
Discussion
Adequate radiologic evaluation for responses of primary tumor and metastatic regional lymph nodes after CCRT is important. It was reported that MRI measurement of primary lesion 6-8 weeks after RADPLAT was very useful [9] . van den Broek et al. reported that patients with focal masses \10 mm could omit biopsy under general anesthesia. These criteria using MRI are considered to be effective for primary tumor evaluation. However, failure of the CCRT to control disease within regional lymph nodes is an indication to perform salvage. It is important to find early failure not to miss the chance of surgical salvage. Therefore, accurate evaluation during the early post-CCRT period is needed.
A previous study reported that defined rCR using the criterion of no focal abnormality and a maximum diameter of less than 15 mm after radiation therapy (RT), found the NPV to be 94% [7] . Ojiri et al. applied the same criterion to evaluate nodal response for post-RT patients and reported an NPV accuracy of 96.6-100%; it therefore appeared feasible to decide whether to perform salvage ND using such criteria [10] . When we applied this criterion, the NPV was 88.5%, PPV was 69.2%, and the positive likelihood ratio was 7.50, which is comparable to recent reports.
An ultrasonography (US) study used an alternative criterion of different nodal sizes for different levels of the neck [8] . This suggested that a minimal axial diameter of 7 mm in level II nodes and 6 mm for the rest of the neck represents a reasonable compromise between sensitivity and specificity (sensitivity, 80%; specificity, 59%; NPV, 75%; PPV, 66%). This was deemed suitable for CT, and regarded as useful in the evaluation of nodal response after CCRT and RADPLAT. We applied this criterion after RADPLAT, and achieved an NPV of 90.5%, a PPV of 47.8%, and a positive likelihood ratio of 3.06.
Our study used two criteria to evaluate rCR and, consequently, observed a significant difference between McNemar's test: p = 0.0016 ''Criterion 1'' defined less than 15 mm maximum diameter and no focal abnormality as radiographic node negative ''Criterion 2'' defined less than 7 mm minimum diameter in level II and less than 6 mm minimum diameter in rest of neck,and no focal abnormality as radiographic node negative as radiographic node negative US-FNAC ultrasound-guided fine-needle aspiration cytology, PET positron emission tomography, CT computed tomography, IMRT intensitymodulated radiation treatment, RADPLAT superselective intra-arterial infusion of cisplatin and concomitant radiotherapy, NPV negative predictive value, PPV positive predictive value criteria 1 and 2 using McNemar's test (p = 0.0016), although the NPV of the two criteria compared favorably. In terms of positive likelihood ratios, criterion 1 had the advantage of reliability over criterion 2 and was much easier to apply. As so few studies of nodal evaluation and criteria after CCRT have been reported, the current investigation might assist in the definition of rCR after CCRT. Some reports have favored the use of positron emission tomography (PET) and PET-CT in assessing treatment response (giving a NPV between 94 and 100%) [11] [12] [13] . However, the appropriate time for PET and PET-CT was under consideration. Yao et al. recommended PET study was best obtained between 12 and 20 weeks after completion of treatment [12] , but it was possible that 12-20 weeks after initial treatment was too late to perform early salvage surgery. However Malone et al. have indicated that PET-CT done 8 weeks post-treatment has a reliable negative predictive value, which offers an alternative to relying on CT scans alone [13] .
Using US-guided fine-needle aspiration cytology, it was reported that specificity was low [14] . However, Doppler blood flow and elastography of US were shown to be effective evaluators of nodal response after initial treatment [15] , which offered the advantages of convenience and minimal invasion. Although it will be necessary to reduce disparities in diagnostic levels between testers, the role of US is expected to take on greater importance in the future.
In recent review, it was reported that planned ND after CCRT was not justified [4] . For patients undergoing RADPLAT, that situation was considered to be same. In our study, the 5-year nodal control rate of RADPLAT alone was high (75.3%). Therefore, the benefits of planned ND were considered to be small. Our study also showed that nodal response assessment of CT after initial treatment was feasible (giving a NPV between 88.5 and 90.5%), so approved a ''wait and see'' policy for RADPLAT treatment.
Conclusions
The accuracy of CT evaluation for nodal response postcompletion of RADPLAT in the present study was comparable to recent reports, and it appeared feasible to decide whether to perform salvage ND following CT evaluation of nodal response. For those patients evaluated as rCR after RADPLAT, the ''wait and see'' policy was deemed acceptable. In addition, we recommend applying criterion 1 (less than 15 mm maximum diameter and no focal abnormality were defined as rCR) for CT evaluation after completion of RADPLAT.
